BEAT HeartBeam Inc

CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, today announced that Humana, a large healthcare third-party payor, upgraded the CardioNet System to a �covered benefit� status. Previously, the CardioNet System was categorized by Humana as �experimental-investigational.� Humana�s 11 million covered members will have access to coverage for prescriptions for the CardioNet System effective September 1, 2008, subject to normal insurance policy guidelines. Humana�s decision was impacted by the peer-reviewed results of a 300-patient randomized clinical trial published in the March 2007 issue of the Journal of Cardiovascular Electrophysiology, demonstrating that the CardioNet System provided a significantly higher diagnostic yield compared to traditional loop event monitoring for patients who had non-diagnostic Holter monitoring. �With the addition of Humana, CardioNet now has secured direct contracts with payors covering 188 million lives or 75% of targeted covered lives. The Humana decision follows a similar decision from another large third-party payor representing 16 million lives that we announced in March 2008. We expect that the clinical evidence from the trial will continue to drive physician adoption of our service and assist in our securing contracts with additional commercial payors,� said Arie Cohen, CardioNet Chief Executive Officer. About CardioNet CardioNet, Inc. is a leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual�s health. CardioNet�s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as the CardioNet System. More information can be found at http://www.cardionet.com. Forward Looking Statements This press release includes certain forward-looking statements within the meaning of the �Safe Harbor� provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our ability to secure contracts with additional commercial payors and the positive impact of our clinical study on that process. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, the success of our sales and marketing initiatives, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development and marketing, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection and litigation. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.